Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

According to the article, that investor aims to influence the company's choice of a chief executive.

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

The current health news highlights a series of dynamic events, including Parvus Asset Management's stake in Novo Nordisk, WHO ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...